Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal
expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or …

Patients with polycythemia vera (PV), a myeloproliferative neoplasm characterized by an
elevated red blood cell mass, are at high risk of vascular and thrombotic complications and …

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by aberrant myeloid
lineage hematopoiesis with excessive red blood cell and pro-inflammatory cytokine …

Polycythemia vera (PV) is a Philadelphia chromosomeâ negative chronic myeloproliferative
neoplasm that is associated with a Janus kinase 2 (JAK2) mutation in most cases. The most …

Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …

Polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm
that results in increased myeloproliferation. It is a debilitating disease characterized by the …

Polycythemia vera is one of three stem-cell–derived myeloid malignancies commonly known
as myeloproliferative neoplasms. It is characterized by erythrocytosis, often with associated …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by an
overactive Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway …

Patients with polycythemia vera (PV) experience shortened survival, increased risk of
thromboembolic and hemorrhagic events, and burdensome symptoms. For all patients with …